203 related articles for article (PubMed ID: 36442769)
21. Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation: A single center study.
Lu Y; Zhang JP; Zhao YL; Xiong M; Sun RJ; Cao XY; Wei ZJ; Zhou JR; Liu DY; Yang JF; Zhang X; Lu DP; Lu P
Front Immunol; 2022; 13():1066748. PubMed ID: 36685540
[TBL] [Abstract][Full Text] [Related]
22. Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation.
Farhadfar N; Dias A; Wang T; Fretham C; Chhabra S; Murthy HS; Broglie L; D'Souza A; Gadalla SM; Gale RP; Hashmi S; Al-Homsi AS; Hildebrandt GC; Hematti P; Rizzieri D; Chee L; Lazarus HM; Bredeson C; Jaimes EA; Beitinjaneh A; Bashey A; Prestidge T; Krem MM; Marks DI; Benoit S; Yared JA; Nishihori T; Olsson RF; Freytes CO; Stadtmauer E; Savani BN; Sorror ML; Ganguly S; Wingard JR; Pasquini M
Transplant Cell Ther; 2021 May; 27(5):410-422. PubMed ID: 33775617
[TBL] [Abstract][Full Text] [Related]
23. Early immune reconstitution as predictor for outcomes after allogeneic hematopoietic cell transplant; a tri-institutional analysis.
Troullioud Lucas AG; Lindemans CA; Bhoopalan SV; Dandis R; Prockop SE; Naik S; Keerthi D; de Koning C; Sharma A; Nierkens S; Boelens JJ
Cytotherapy; 2023 Sep; 25(9):977-985. PubMed ID: 37330731
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation.
Acosta-Medina AA; Baranwal A; Johnson IM; Kharfan-Dabaja MA; Murthy H; Palmer JM; Sproat L; Mangaonkar A; Shah MV; Hogan WJ; Litzow MR; Tefferi A; Alkhateeb HB
Transplant Cell Ther; 2023 Jun; 29(6):360.e1-360.e8. PubMed ID: 36773650
[TBL] [Abstract][Full Text] [Related]
25. Refinement of the Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation.
Shibasaki Y; Suwabe T; Katagiri T; Tanaka T; Ushiki T; Fuse K; Sato N; Yano T; Kuroha T; Hashimoto S; Narita M; Furukawa T; Sone H; Masuko M
Int J Hematol; 2018 Sep; 108(3):282-289. PubMed ID: 29744806
[TBL] [Abstract][Full Text] [Related]
26. Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT.
Penack O; Peczynski C; Mohty M; Yakoub-Agha I; de la Camara R; Glass B; Duarte RF; Kröger N; Schoemans H; Koenecke C; Peric Z; Basak GW
Bone Marrow Transplant; 2022 Feb; 57(2):183-190. PubMed ID: 34718346
[TBL] [Abstract][Full Text] [Related]
27. Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
Carré M; Porcher R; Finke J; Ehninger G; Koster L; Beelen D; Ganser A; Volin L; Lozano S; Friis L; Michallet M; Tischer J; Olavarria E; Cascon MJP; Iacobelli S; Koc Y; Jindra P; Arat M; de Witte T; Yakoub Agha I; Kröger N; Robin M
Biol Blood Marrow Transplant; 2020 Mar; 26(3):451-457. PubMed ID: 31647984
[TBL] [Abstract][Full Text] [Related]
28. Hematopoietic Cell Transplantation Trends and Outcomes in Canada: A Registry-Based Cohort Study.
Seftel MD; Pasic I; Parmar G; Bucher O; Allan DS; Bhella S; Hay KA; Ikuomola O; Musto G; Prica A; Richardson E; Truong TH; Paulson K
Curr Oncol; 2023 Nov; 30(11):9953-9967. PubMed ID: 37999143
[No Abstract] [Full Text] [Related]
29. Hematopoietic Cell Transplantation-Comorbidity Index Score Is Correlated with Treatment-Related Mortality and Overall Survival following Second Allogeneic Hematopoietic Cell Transplantation in Children.
Forlanini F; Zinter MS; Dvorak CC; Bailey-Olson M; Winestone LE; Shimano KA; Higham CS; Melton A; Chu J; Kharbanda S
Transplant Cell Ther; 2022 Mar; 28(3):155.e1-155.e8. PubMed ID: 34848362
[TBL] [Abstract][Full Text] [Related]
30. Assessment of ST2 for risk of death following graft-versus-host disease in pediatric and adult age groups.
Rowan CM; Pike F; Cooke KR; Krance R; Carpenter PA; Duncan C; Jacobsohn DA; Bollard CM; Cruz CRY; Malatpure A; Farag SS; Renbarger J; Liu H; Bakoyannis G; Hanash S; Paczesny S
Blood; 2020 Apr; 135(17):1428-1437. PubMed ID: 31972009
[TBL] [Abstract][Full Text] [Related]
31. Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in a retrospective cohort of children and adolescents who received an allogeneic transplantation in Argentina.
Figueroa Turienzo CM; Cernadas C; Roizen M; Pizzi S; Staciuk R
Arch Argent Pediatr; 2016 Aug; 114(4):337-42. PubMed ID: 27399011
[TBL] [Abstract][Full Text] [Related]
32. Limitations of Applying the Hematopoietic Cell Transplantation Comorbidity Index in Pediatric Patients Receiving Allogeneic Hematopoietic Cell Transplantation.
Broglie L; Ruiz J; Jin Z; Kahn JM; Bhatia M; George D; Garvin J; Satwani P
Transplant Cell Ther; 2021 Jan; 27(1):74.e1-74.e9. PubMed ID: 33039515
[TBL] [Abstract][Full Text] [Related]
33. Validation of a Hematopoietic Cell Transplant-Composite Risk (HCT-CR) Model for Post-Transplant Survival Prediction in Patients with Hematologic Malignancies.
Ciurea SO; Kongtim P; Hasan O; Ramos Perez JM; Torres J; Rondon G; Champlin RE
Clin Cancer Res; 2020 May; 26(10):2404-2410. PubMed ID: 32019857
[TBL] [Abstract][Full Text] [Related]
34. Risk Assessment in Adult T Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation.
Yoshimitsu M; Tanosaki R; Kato K; Ishida T; Choi I; Takatsuka Y; Fukuda T; Eto T; Hidaka M; Uchida N; Miyamoto T; Nakashima Y; Moriuchi Y; Nagafuji K; Miyazaki Y; Ichinohe T; Takanashi M; Atsuta Y; Utsunomiya A;
Biol Blood Marrow Transplant; 2018 Apr; 24(4):832-839. PubMed ID: 29155320
[TBL] [Abstract][Full Text] [Related]
35. Assessing the Influence of Different Comorbidities Indexes on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in a Developing Country.
Teixeira GM; Bittencourt H; de Macedo AV; Martinho GH; Colosimo EA; Rezende SM
PLoS One; 2015; 10(9):e0137390. PubMed ID: 26394228
[TBL] [Abstract][Full Text] [Related]
36. Impact of muscle loss in children with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation.
Suzuki D; Kobayashi R; Yamamoto M; Matsushima S; Hori D; Yanagi M; Kodama K; Sano H; Akane Y; Igarashi K; Kobayashi K
Int J Hematol; 2023 Jan; 117(1):128-133. PubMed ID: 36168084
[TBL] [Abstract][Full Text] [Related]
37. Increased Health Care Utilization and Costs during Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndromes in Adolescents and Young Adults Compared with Children: A Multicenter Study.
Rangarajan HG; Smith LC; Stanek JR; Hall M; Abu-Arja R; Auletta JJ; O'Brien SH
Biol Blood Marrow Transplant; 2019 May; 25(5):1031-1038. PubMed ID: 30625391
[TBL] [Abstract][Full Text] [Related]
38. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies.
Naik S; Martinez C; Leung K; Sasa G; Nguyen NY; Wu MF; Gottschalk S; Brenner M; Heslop H; Krance R
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1266-72. PubMed ID: 25765555
[TBL] [Abstract][Full Text] [Related]
39. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.
Keller JW; Andreadis C; Damon LE; Kaplan LD; Martin TG; Wolf JL; Ai WZ; Venstrom JM; Smith CC; Gaensler KM; Hwang J; Olin RL
J Geriatr Oncol; 2014 Jul; 5(3):238-44. PubMed ID: 24894413
[TBL] [Abstract][Full Text] [Related]
40. Discontinuation and Nonadherence to Medications for Chronic Conditions after Hematopoietic Cell Transplantation: A 6-Year Propensity Score-Matched Cohort Study.
Zhou J; Han J; Nutescu EA; Patel PR; Sweiss K; Calip GS
Pharmacotherapy; 2019 Jan; 39(1):55-66. PubMed ID: 30485471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
